Prothena Corporation plc

NASDAQ PRTA

Download Data

Prothena Corporation plc Market Capitalization on April 12, 2024: USD 1.19 B

Prothena Corporation plc Market Capitalization is USD 1.19 B on April 12, 2024, a -56.60% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.
  • Prothena Corporation plc 52-week high Market Capitalization is USD 4.18 B on May 05, 2023, which is 250.12% above the current Market Capitalization.
  • Prothena Corporation plc 52-week low Market Capitalization is USD 1.19 B on April 12, 2024, which is 0.00% below the current Market Capitalization.
  • Prothena Corporation plc average Market Capitalization for the last 52 weeks is USD 2.53 B.
SV Wall Street

Don’t Miss A Beat

Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.

NASDAQ: PRTA

Prothena Corporation plc

CEO Dr. Gene G. Kinney Ph.D.
IPO Date Dec. 21, 2012
Location Ireland
Headquarters 77 Sir John Rogerson?s Quay, Dublin, Ireland, 2
Employees 173
Sector Healthcare
Industry Biotechnology
Description

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Similar companies

MIST

Milestone Pharmaceuticals Inc

USD 1.73

1.76%

STOK

Stoke Therapeutics Inc

USD 12.77

-5.41%

CGEM

Cullinan Oncology LLC

USD 16.67

-4.03%

StockViz Staff

April 14, 2024

Any question? Send us an email